1. Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to phase II clinical research in idiopathic pulmonary fibrosis. News release. Boehringer-Ingelheim. January 13, 2026. Accessed ...

Experts discuss the current status of neoadjuvant ADC therapies, eligibility criteria, and future treatment pathways for high-risk patients.

Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors.

Psychiatric disorders such as anxiety and depression are connected with a range of chronic health conditions, including cancer. 3 Potential causative links are psychological stress and poor health ...

Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast ...

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in ...

As the FY26 budget is being negotiated, Jennifer Snow, MPA, of NAMI, emphasizes that funds must be directed to programs as ...

The Coalition’s Conversation podcast series is a 3-part discussion on how employers can incorporate glucagon-like peptide-1 ...

The authors of the study and the editorial note that a primary limitation on these findings is the concentration of Medicare ...

The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating safety and efficacy over 12 weeks. Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis ...

Infant protection against respiratory syncytial virus (RSV) by maternal RSV vaccination or receipt of RSV monoclonal antibody ...

Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting ...